Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Anorexia and EGFR[original query] |
---|
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis. PloS one 2013 8 (11): e79000. OuYang Pu-Yun, Su Zhen, Mao Yan-Ping, Deng Wuguo, Xie Fang-Y |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Current oncology reports 2014 Jun 16 (6): 390. Yang XiongWen, Yang Ke, Kuang Kang |
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology 2015 1 26 (5): 998-1005. Wong A L, Soo R A, Tan D S, Lee S C, Lim J S, Marban P C, Kong L R, Lee Y J, Wang L Z, Thuya W L, Soong R, Yee M Q, Chin T M, Cordero M T, Asuncion B R, Pang B, Pervaiz S, Hirpara J L, Sinha A, Xu W W, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh B |
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001). Molecular and clinical oncology 2017 Mar 6 (3): 409-414. Miyawaki Masayoshi, Naoki Katsuhiko, Yoda Satoshi, Nakayama Sohei, Satomi Ryosuke, Sato Takashi, Ikemura Shinnosuke, Ohgino Keiko, Ishioka Kota, Arai Daisuke, Namkoong Ho, Otsuka Kengo, Miyazaki Masaki, Tani Tetsuo, Kuroda Aoi, Nishino Makoto, Yasuda Hiroyuki, Kawada Ichiro, Koh Hidefumi, Nakamura Morio, Terashima Takeshi, Sakamaki Fumio, Sayama Koichi, Betsuyaku Tomoko, Soejima Ken |
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations. Investigational new drugs 2017 11 36 (4): 608-614. Tamiya Motohiro, Tamiya Akihiro, Shiroyama Takayuki, Takeoka Sawa, Naito Yujiro, Omachi Naoki, Kimura Yohei, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Okishio Kyoichi, Kawaguchi Tomoya, Atagi Shinji, Hirashima Tomono |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer chemotherapy and pharmacology 2018 May . Imai Hisao, Minemura Hiroyuki, Sugiyama Tomohide, Yamada Yutaka, Kaira Kyoichi, Kanazawa Kenya, Kasai Takashi, Kaburagi Takayuki, Minato Koichi, |
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical oncology (Northwood, London, England) 2018 2 35 (3): 34. Tanaka Hisashi, Taima Kageaki, Tanaka Yoshihito, Itoga Masamichi, Ishioka Yoshiko, Nakagawa Hideyuki, Baba Keisuke, Hasegawa Yukihiro, Takanashi Shingo, Tasaka Sadato |
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. Lung cancer (Amsterdam, Netherlands) 2018 1 115 103-108. Ninomiya Takashi, Nogami Naoyuki, Kozuki Toshiyuki, Harada Daijiro, Kubo Toshio, Ohashi Kadoaki, Kuyama Shoichi, Kudo Kenichiro, Bessho Akihiro, Fukamatsu Nobuaki, Fujimoto Nobukazu, Aoe Keisuke, Shibayama Takuo, Sugimoto Keisuke, Takigawa Nagio, Hotta Katsuyuki, Kiura Katsuyu |
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. Journal of clinical medicine 2020 Jun 9 (6): . Nakao Akira, Hiranuma Osamu, Uchino Junji, Sakaguchi Chikara, Araya Tomoyuki, Hiraoka Noriya, Ishizuka Tamotsu, Takeda Takayuki, Kawasaki Masayuki, Goto Yasuhiro, Imai Hisao, Hattori Noboru, Nakatomi Keita, Uramoto Hidetaka, Uryu Kiyoaki, Fukuda Minoru, Uchida Yasuki, Yokoyama Toshihide, Akai Masaya, Mio Tadashi, Nagashima Seiji, Chihara Yusuke, Tamiya Nobuyo, Kaneko Yoshiko, Mouri Takako, Yamada Tadaaki, Yoshimura Kenichi, Fujita Masaki, Takayama Koic |
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Kaunas, Lithuania) 2021 9 57 (9): . Yamada Yutaka, Imai Hisao, Sugiyama Tomohide, Minemura Hiroyuki, Kanazawa Kenya, Kasai Takashi, Minato Koichi, Kaira Kyoichi, Kaburagi Takayu |
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer. ERJ open research 2022 10 8 (4): . Gijtenbeek Rolof G P, van der Noort Vincent, Aerts Joachim G J V, Staal-van den Brekel Jeske A, Smit Egbert F, Krouwels Frans H, Wilschut Frank A, Hiltermann T Jeroen N, Timens Wim, Schuuring Ed, Janssen Joost D J, Goosens Martijn, van den Berg Paul M, de Langen A Joop, Stigt Jos A, van den Borne Ben E E M, Groen Harry J M, van Geffen Wouter H, van der Wekken Anthonie |
A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety. Biomedicines 2023 9 11 (9): . Tatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa, Ryotaro Igusa, Hayato Yokota, Kana Watanabe, Aya Suzuki, Mami Morita, Ren Onodera, Akira Inoue, Masatomo Miura, Yoshihiro Minamiya, Makoto Maemon |
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 2023 1 . Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kasai Hidefumi, Kuniyoshi Ouki, Kimura Motonori, Hakamata Jun, Nakada Hideo, Suehiro Naoya, Nakaya Naoki, Nakajima Hideo, Ikemura Shinnosuke, Kawada Ichiro, Yasuda Hiroyuki, Terai Hideki, Jibiki Aya, Kawazoe Hitoshi, Soejima Kenzo, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomono |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 20, 2024
- Content source: